Literature DB >> 7619080

Modulation of the phosphorylation state of tau in situ: the roles of calcium and cyclic AMP.

L M Fleming1, G V Johnson.   

Abstract

Alterations in situ in the phosphorylation state of the microtubule-associated protein tau were examined in response to increasing intracellular levels of Ca2+ through N-methyl-D-aspartate (NMDA)-receptor activation, or activating cyclic AMP (cAMP)-dependent protein kinase (cAMP-PK), in rat cerebral-cortical slices. Increasing intracellular concentrations of Ca2+ by treatment of the brain slices with the glutamate analogue NMDA in depolarizing conditions (55 mM KCl) resulted in dephosphorylation of tau. Addition of KCl+NMDA to the slices resulted in a 40% decrease in 32P incorporation into tau, whereas addition of KCl or NMDA alone had no effect on tau phosphorylation. The KCl+NMDA-induced dephosphorylation of tau was blocked by the non-competitive NMDA-receptor antagonist MK801. Determine the involvement of the Ca2+/calmodulin-dependent phosphatase, calcineurin, in the KCl+NMDA-induced dephosphorylation of tau, slices were pretreated with the calcineurin inhibitor Cyclosporin A. Pretreatment of the rat brain slices with Cyclosporin A completely abolished the dephosphorylation of tau induced by the addition of KCl+NMDA. The dephosphorylation of tau in situ was site-selective, as indicated by the loss of 32P label from only a few select peptides. Activation of cAMP-PK by stimulating adenylate cyclase in rat cerebral-cortical slices with forskolin resulted in a 73% increase over control levels in 32P incorporation into immunoprecipitated tau. Two-dimensional phosphopeptide mapping revealed that most of the sites on tau phosphorylated in brain slices in response to increased cAMP levels were the same as those phosphorylated on isolated tau by purified cAMP-PK. Although the state of tau phosphorylation is certainly regulated by many protein phosphatases and kinases in vivo, to our knowledge this study provides the first direct evidence of a specific protein phosphatase and kinase that modulate the phosphorylation state of tau in situ.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7619080      PMCID: PMC1135797          DOI: 10.1042/bj3090041

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  53 in total

1.  Differential phosphorylation of tau by cyclic AMP-dependent protein kinase and Ca2+/calmodulin-dependent protein kinase II: metabolic and functional consequences.

Authors:  G V Johnson
Journal:  J Neurochem       Date:  1992-12       Impact factor: 5.372

2.  The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs.

Authors:  N Gustke; B Steiner; E M Mandelkow; J Biernat; H E Meyer; M Goedert; E Mandelkow
Journal:  FEBS Lett       Date:  1992-07-28       Impact factor: 4.124

3.  Phosphorylation of recombinant tau by cAMP-dependent protein kinase. Identification of phosphorylation sites and effect on microtubule assembly.

Authors:  C W Scott; R C Spreen; J L Herman; F P Chow; M D Davison; J Young; C B Caputo
Journal:  J Biol Chem       Date:  1993-01-15       Impact factor: 5.157

4.  High external potassium induces an increase in the phosphorylation of the cytoskeletal protein MAP2 in rat hippocampal slices.

Authors:  J Díaz-Nido; R J Montoro; J López-Barneo; J Avila
Journal:  Eur J Neurosci       Date:  1993-07-01       Impact factor: 3.386

5.  Casein kinase II preferentially phosphorylates human tau isoforms containing an amino-terminal insert. Identification of threonine 39 as the primary phosphate acceptor.

Authors:  J A Greenwood; C W Scott; R C Spreen; C B Caputo; G V Johnson
Journal:  J Biol Chem       Date:  1994-02-11       Impact factor: 5.157

6.  Alzheimer's disease abnormally phosphorylated tau is dephosphorylated by protein phosphatase-2B (calcineurin).

Authors:  C X Gong; T J Singh; I Grundke-Iqbal; K Iqbal
Journal:  J Neurochem       Date:  1994-02       Impact factor: 5.372

7.  p42 MAP kinase phosphorylation sites in microtubule-associated protein tau are dephosphorylated by protein phosphatase 2A1. Implications for Alzheimer's disease [corrected].

Authors:  M Goedert; E S Cohen; R Jakes; P Cohen
Journal:  FEBS Lett       Date:  1992-11-02       Impact factor: 4.124

8.  Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity.

Authors:  T M Dawson; J P Steiner; V L Dawson; J L Dinerman; G R Uhl; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-01       Impact factor: 11.205

9.  Phosphorylation, calpain proteolysis and tubulin binding of recombinant human tau isoforms.

Authors:  J M Litersky; C W Scott; G V Johnson
Journal:  Brain Res       Date:  1993-02-26       Impact factor: 3.252

10.  Overexpression of tau in a nonneuronal cell induces long cellular processes.

Authors:  J Knops; K S Kosik; G Lee; J D Pardee; L Cohen-Gould; L McConlogue
Journal:  J Cell Biol       Date:  1991-08       Impact factor: 10.539

View more
  18 in total

1.  Energy metabolism and protein phosphorylation during apoptosis: a phosphorylation study of tau and high-molecular-weight tau in differentiated PC12 cells.

Authors:  P K Davis; G V Johnson
Journal:  Biochem J       Date:  1999-05-15       Impact factor: 3.857

2.  The origin and development of plaques and phosphorylated tau are associated with axonopathy in Alzheimer's disease.

Authors:  Ai-Wu Xiao; Jing He; Qian Wang; Yi Luo; Yan Sun; Yan-Ping Zhou; Yang Guan; Paul J Lucassen; Jia-Pei Dai
Journal:  Neurosci Bull       Date:  2011-10       Impact factor: 5.203

Review 3.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration.

Authors:  M L Billingsley; R L Kincaid
Journal:  Biochem J       Date:  1997-05-01       Impact factor: 3.857

4.  Helicity of alpha(404-451) and beta(394-445) tubulin C-terminal recombinant peptides.

Authors:  M A Jimenez; J A Evangelio; C Aranda; A Lopez-Brauet; D Andreu; M Rico; R Lagos; J M Andreu; O Monasterio
Journal:  Protein Sci       Date:  1999-04       Impact factor: 6.725

5.  Depotentiation of Long-Term Potentiation Is Associated with Epitope-Specific Tau Hyper-/Hypophosphorylation in the Hippocampus of Adult Rats.

Authors:  Ercan Babür; Burak Tan; Sumeyra Delibaş; Marwa Yousef; Nurcan Dursun; Cem Süer
Journal:  J Mol Neurosci       Date:  2018-11-29       Impact factor: 3.444

Review 6.  Glutamate system, amyloid ß peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology.

Authors:  Timothy J Revett; Glen B Baker; Jack Jhamandas; Satyabrata Kar
Journal:  J Psychiatry Neurosci       Date:  2013-01       Impact factor: 6.186

7.  N-methyl-D-aspartate receptor blockade reduces plasticity-related tau expression and phosphorylation of tau at Ser416 residue but not Thr231 residue.

Authors:  Burak Tan; Ezgi Aslan-Gülpınar; Nurcan Dursun; Cem Süer
Journal:  Exp Brain Res       Date:  2021-03-25       Impact factor: 1.972

8.  Glycine Administration Alters MAPK Signaling Pathways and Causes Neuronal Damage in Rat Brain: Putative Mechanisms Involved in the Neurological Dysfunction in Nonketotic Hyperglycinemia.

Authors:  Alana Pimentel Moura; Belisa Parmeggiani; Juciano Gasparotto; Mateus Grings; Gabriela Miranda Fernandez Cardoso; Bianca Seminotti; José Cláudio Fonseca Moreira; Daniel Pens Gelain; Moacir Wajner; Guilhian Leipnitz
Journal:  Mol Neurobiol       Date:  2017-01-03       Impact factor: 5.590

9.  Blockade of NR2A-containing NMDA receptors induces Tau phosphorylation in rat hippocampal slices.

Authors:  Julie Allyson; Eve Dontigny; Yves Auberson; Michel Cyr; Guy Massicotte
Journal:  Neural Plast       Date:  2010-05-20       Impact factor: 3.599

10.  The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer's disease.

Authors:  S Illenberger; Q Zheng-Fischhöfer; U Preuss; K Stamer; K Baumann; B Trinczek; J Biernat; R Godemann; E M Mandelkow; E Mandelkow
Journal:  Mol Biol Cell       Date:  1998-06       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.